Breast Cancer and HER2+

The Breast Cancer Channel on VJOncology is supported by Gilead. These supporters have no influence over the production of the content.

View overview page
0:53
TUXEDO-1: T-DXd for patients with HER2-positive breast cancer and brain metastasis
Rupert Bartsch • 5 May 2022
1:55
Investigating anthracycline, taxane and trastuzumab-based neoadjuvant chemotherapy in HER2+ eBC
Benedetta Conte • 5 May 2022
1:26
The association of the HER2DX signatures with survival in TNBC
Benedetta Conte • 5 May 2022
0:59
The significance of HER2 expression for the activity of trastuzumab deruxtecan
Maria Fernanda Mosele • 5 May 2022
2:05
PerELISA: overexpression of 13 genes associated with endocrine sensitivity in HR+/HER2+ BC
Gaia Griguolo • 3 May 2022
1:17
PerELISA: de-escalated therapy for HR+/HER2+ BC with Ki67 response following 2-week letrozole
Gaia Griguolo • 3 May 2022
1:23
Antibody-drug conjugates for the treatment of breast cancer
Paolo Tarantino • 3 May 2022
1:16
HER2-low expression in breast cancer
Paolo Tarantino • 3 May 2022
1:09
The exciting new field of HER2-low breast cancer
Paolo Tarantino • 3 May 2022
1:49
The latest clinical research on ADCs in breast cancer
Paolo Tarantino • 3 May 2022
1:29
TUXEDO-1: trastuzumab deruxtecan for the treatment of HER2-positive breast cancer brain metastases
Gaia Griguolo • 3 May 2022
1:29
Poziotinib for HER2-positive metastatic breast cancer
Yeon Hee Park • 3 May 2022
3:18
Molecular heterogeneity in HER2+ breast cancer and predicting outcomes
Aleix Prat • 7 Dec 2021
2:46
Prognostic impact of immune interactions in patients with HER2+ and TNBC with brain metastases
Gaia Griguolo • 21 Sep 2021
2:38
HER2+ and TNBC highlights from ESMO 2021
Gaia Griguolo • 21 Sep 2021
1:55
Advances in treatments for HER2-positive metastatic breast cancer
Cristina Saura Manich • 29 Sep 2021

The Breast Cancer Channel on VJOncology is supported by Gilead.

These supporters have no influence over the production of the content.

If you are interested in becoming a supporter of The Breast Cancer Channel, please contact us.
The content of VJOncology is intended for healthcare professionals